PortfoliosLab logoPortfoliosLab logo
TMED vs. IDNA
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

TMED vs. IDNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in T. Rowe Price Health Care ETF (TMED) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, TMED achieves a 10.47% return, which is significantly lower than IDNA's 21.59% return.


TMED

1D
1.71%
1M
5.92%
YTD
10.47%
6M
9.58%
1Y
33.64%
3Y*
5Y*
10Y*

IDNA

1D
1.73%
1M
8.13%
YTD
21.59%
6M
18.20%
1Y
53.56%
3Y*
11.80%
5Y*
-7.99%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

TMED vs. IDNA - Yearly Performance Comparison


Correlation

The correlation between TMED and IDNA is 0.79, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.79

Correlation (All Time)
Calculated using the full available price history since Jun 12, 2025

0.79

The correlation between TMED and IDNA has been stable across timeframes, ranging from 0.79 to 0.79 - a consistent structural relationship.

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

TMED vs. IDNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TMED
TMED Risk / Return Rank: 6666
Overall Rank
TMED Sharpe Ratio Rank: 6666
Sharpe Ratio Rank
TMED Sortino Ratio Rank: 6969
Sortino Ratio Rank
TMED Omega Ratio Rank: 6161
Omega Ratio Rank
TMED Calmar Ratio Rank: 7070
Calmar Ratio Rank
TMED Martin Ratio Rank: 6464
Martin Ratio Rank

IDNA
IDNA Risk / Return Rank: 7777
Overall Rank
IDNA Sharpe Ratio Rank: 7676
Sharpe Ratio Rank
IDNA Sortino Ratio Rank: 7575
Sortino Ratio Rank
IDNA Omega Ratio Rank: 6363
Omega Ratio Rank
IDNA Calmar Ratio Rank: 9090
Calmar Ratio Rank
IDNA Martin Ratio Rank: 8080
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TMED vs. IDNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for T. Rowe Price Health Care ETF (TMED) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


TMEDIDNADifference
Sharpe ratioReturn per unit of total volatility

-0.30

Sortino ratioReturn per unit of downside risk

-0.27

Omega ratioGain probability vs. loss probability

1.32

1.34

-0.02

Calmar ratioReturn relative to maximum drawdown

3.04

5.05

-2.01

Martin ratioReturn relative to average drawdown

9.95

14.08

-4.13

TMED vs. IDNA - Sharpe Ratio Comparison

The current TMED Sharpe Ratio is 1.86, which is comparable to the IDNA Sharpe Ratio of 2.16. The chart below compares the historical Sharpe Ratios of TMED and IDNA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

TMED vs. IDNA - Drawdown Comparison

The maximum TMED drawdown since its inception was -11.11%, smaller than the maximum IDNA drawdown of -68.26%. Use the drawdown chart below to compare losses from any high point for TMED and IDNA.


Loading charts...

Drawdown Indicators


TMEDIDNADifference

Max Drawdown

Largest peak-to-trough decline

-11.11%

-68.26%

+57.15%

Max Drawdown (1Y)

Largest decline over 1 year

-11.11%

-10.66%

-0.45%

Max Drawdown (3Y)

Largest decline over 3 years

-29.46%

Max Drawdown (5Y)

Largest decline over 5 years

-68.26%

Current Drawdown

Current decline from peak

0.00%

-40.05%

+40.05%

Average Drawdown

Average peak-to-trough decline

-2.47%

-36.28%

+33.81%

Ulcer Index

Depth and duration of drawdowns from previous peaks

3.39%

3.82%

-0.43%

Volatility

TMED vs. IDNA - Volatility Comparison

The current volatility for T. Rowe Price Health Care ETF (TMED) is 6.00%, while iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) has a volatility of 7.45%. This indicates that TMED experiences smaller price fluctuations and is considered to be less risky than IDNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


TMEDIDNADifference

Volatility (1M)

Calculated over the trailing 1-month period

6.00%

7.45%

-1.45%

Volatility (6M)

Calculated over the trailing 6-month period

13.61%

18.37%

-4.76%

Volatility (1Y)

Calculated over the trailing 1-year period

18.21%

25.00%

-6.79%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

18.08%

28.47%

-10.39%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

18.08%

29.51%

-11.43%

TMED vs. IDNA - Expense Ratio Comparison

TMED has a 0.44% expense ratio, which is lower than IDNA's 0.47% expense ratio.


Dividends

TMED vs. IDNA - Dividend Comparison

TMED's dividend yield for the trailing twelve months is around 0.49%, less than IDNA's 0.89% yield.


PositionTTM2025202420232022202120202019
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund
0.89%1.18%0.98%1.04%0.54%0.70%0.26%0.80%
TMED
T. Rowe Price Health Care ETF
0.49%0.54%0.00%0.00%0.00%0.00%0.00%0.00%

Frequently Asked Questions


TMED and IDNA have a correlation of 0.79, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

IDNA has higher volatility (7.45%) compared to TMED (6.00%). In terms of maximum drawdown, TMED dropped -11.11% vs IDNA's -68.26%.

On 1-year performance, IDNA leads with 53.56% vs 33.64% for TMED. On fees, TMED is cheaper at 0.44% per year. On volatility, TMED has been the lower-risk option at 6.00%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 1-year period, IDNA has performed better with a 53.56% return vs 33.64%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

TMED is cheaper with a 0.44% expense ratio, compared with 0.47% for IDNA.

IDNA has the higher dividend yield at 0.89%, compared with 0.49% for TMED.

They also come from different issuers: T. Rowe Price and iShares. Their fees differ too: 0.44% for TMED and 0.47% for IDNA.

IDNA currently has the higher Sharpe Ratio (2.16 vs 1.86), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for TMED and IDNA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer